investors & media

More events are coming soon.

corporate profile

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

stock quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

press releases


SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease Management team to host conference call Monday, September 19 , at 8:00 a.m. ET SOMERVILLE, Mass. --(BUSINESS WIRE)--Sep.

Read more

Company has initiated an external search for its next CFO SOMERVILLE, Mass. --(BUSINESS WIRE)--Sep. 12, 2022-- bluebird bio, Inc . (NASDAQ: BLUE) today announced that Jason Cole , Chief Strategy and Financial Officer, plans to leave bluebird bio to pursue new career opportunities.​ Throughout his

Read more

SOMERVILLE, Mass. --(BUSINESS WIRE)--Aug. 29, 2022-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 2022 Wells Fargo Healthcare Conference , Thursday, September 8 , at 9:10 a.m.

Read more